Page last updated: 2024-11-07

eudragit-e

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Eudragit-E is a copolymer of methacrylic acid and ethyl acrylate. It is commonly used in pharmaceutical formulations as a film-forming agent for controlled-release drug delivery. Eudragit-E is insoluble in water and has a pH-dependent dissolution profile, meaning it dissolves at a specific pH range. Its ability to form a film allows for the creation of enteric coatings that protect drugs from degradation in the acidic environment of the stomach, ensuring their release in the more alkaline environment of the small intestine. This property is crucial for the safe and effective delivery of medications that are sensitive to stomach acid. The study of Eudragit-E is important to optimize drug delivery systems and improve the bioavailability and effectiveness of medications.'

Eudragit-E: a cationic polymer, used as a embolic material for arteriovenous malformations and as a taste masker [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID107676
SCHEMBL ID427500
MeSH IDM0268994

Synonyms (12)

Synonym
24938-16-7
eudragit-e
eudragit e 100
eudragit e 12.5
eudragit e
eudragit e po
unii-905hno1sih
905hno1sih ,
SCHEMBL427500
NEDGUIRITORSKL-UHFFFAOYSA-N
n,n-dimethylaminoethyl methacrylate methyl methacrylate n-butyl methacrylate
butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic profiling of orally dosed TL formulations in rats was also carried out using UPLC/ESI-MS."( Physicochemical and pharmacokinetic characterization of amorphous solid dispersion of tranilast with enhanced solubility in gastric fluid and improved oral bioavailability.
Aoki, Y; Kawabata, Y; Kojo, Y; Onoue, S; Yamada, S; Yamauchi, Y, 2012
)
0.38

Bioavailability

ExcerptReferenceRelevance
" Thus, it was concluded that DH ODTs with masked taste were obtained by Eudragit EPO-based microspheres, drug loaded microspheres neither decreased the bioavailability nor delayed the release of DH."( Preparation and evaluation of taste-masked donepezil hydrochloride orally disintegrating tablets.
Choi, HG; Kang, JH; Woo, JS; Yan, YD; Yong, CS, 2010
)
0.36
" The bioavailability of andrographolide from optimized nanoparticles and pure andrographolide was assessed in male Wistar albino rats at a dose of 10 mg/kg."( Improved bioavailability of orally administered andrographolide from pH-sensitive nanoparticles.
Chellampillai, B; Pawar, AP, 2011
)
0.37
" After oral administration of the Eudragit EPO-based ASD formulation in rats, enhanced TL exposure was observed with an increase of oral bioavailability by 19-fold, and the variation of AUC was ca."( Physicochemical and pharmacokinetic characterization of amorphous solid dispersion of tranilast with enhanced solubility in gastric fluid and improved oral bioavailability.
Aoki, Y; Kawabata, Y; Kojo, Y; Onoue, S; Yamada, S; Yamauchi, Y, 2012
)
0.38
"In this study, amorphous solid dispersions containing dutasteride and various excipients, manufactured by spray-drying processes, were characterized to determine the effects on their ability to form supersaturated solutions and to identify the effects of supersaturation on increasing the bioavailability of dutasteride."( Improved supersaturation and oral absorption of dutasteride by amorphous solid dispersions.
Beak, IH; Kim, MS, 2012
)
0.38
" Eudragit E nanoparticles containing a drug load of 5% showed an increase in bioavailability by 550% as compared to dutasteride suspension."( Evaluation of in vitro dissolution and in vivo oral absorption of dutasteride-loaded eudragit E nanoparticles.
Kim, MS, 2013
)
0.39
"Serious efforts have been made to overcome the bioavailability problems of ever increasing number of poorly soluble drugs, including atorvastatin (ATO); however, enhancing its gastric solubility has not received much attention."( Amorphous solid dispersion with increased gastric solubility in tandem with oral disintegrating tablets: a successful approach to improve the bioavailability of atorvastatin.
Asghar, S; Lv, H; Salmani, JM; Zhou, J, 2015
)
0.42
"To improve the bioavailability of ATO by increasing its gastric solubility in a stable oral disintegration tablet (ODT) formulation."( Amorphous solid dispersion with increased gastric solubility in tandem with oral disintegrating tablets: a successful approach to improve the bioavailability of atorvastatin.
Asghar, S; Lv, H; Salmani, JM; Zhou, J, 2015
)
0.42
" In vivo results showed an overall enhancement in the apparent bioavailability (83% and 434% more than Lipitor® and plain amorphous ATO tablets, respectively)."( Amorphous solid dispersion with increased gastric solubility in tandem with oral disintegrating tablets: a successful approach to improve the bioavailability of atorvastatin.
Asghar, S; Lv, H; Salmani, JM; Zhou, J, 2015
)
0.42
" Relative bioavailability after oral administration in beagle dogs was assessed."( Application of carrier and plasticizer to improve the dissolution and bioavailability of poorly water-soluble baicalein by hot melt extrusion.
Chen, Y; Han, M; Hu, D; Ke, X; Luo, R; Zhang, Y, 2014
)
0.4
" However, this success is yet to be translated to humans mainly because of its poor oral bioavailability caused by extremely low water solubility."( Molecular complexation of curcumin with pH sensitive cationic copolymer enhances the aqueous solubility, stability and bioavailability of curcumin.
Bhat, GJ; Kesharwani, SS; Kumar, S; Mathur, H; Tummala, H; Tyagi, M, 2016
)
0.43
"Amorphous solid dispersion (ASD) is a formulation strategy extensively used to enhance the bioavailability of poorly water soluble drugs."( The design and development of high drug loading amorphous solid dispersion for hot-melt extrusion platform.
Andrews, GP; Jacobs, E; Jones, DS; McCoy, CP; Tian, Y; Wu, H, 2020
)
0.56
"Bile solubilization and apparent solubility at resorption sites critically affect the bioavailability of orally administered and poorly water-soluble drugs."( Harnessing Bile for Drug Absorption through Rational Excipient Selection.
Endres, S; Galli, B; Hanio, S; Harlacher, C; Lenz, B; Meinel, L; Pöppler, AC; Scherf-Clavel, O; Schlauersbach, J; Werthmüller, D, 2023
)
0.91

Dosage Studied

ExcerptRelevanceReference
" The high flow--limit of gel originating from the tablets as well as its dynamic viscosity should enable durability of this dosage form on the vaginal mucosa."( Studies on gynaecological hydrophilic lactic acid preparations. Part 5: The use of Eudragit E-100 as lactic acid carrier in intravaginal tablets.
Hirnle, L; Kubis, AA; Małolepsza-Jarmołowska, K, 2003
)
0.32
" These aqueous colloidal dispersions of polymeric materials for oral administration are intended for film coating of solid dosage forms or for direct manufacturing of nanoparticles."( Preparation of surfactant-free nanoparticles of methacrylic acid copolymers used for film coating.
Allémann, E; Doelker, E; Fessi, H; Gurny, R; Konan-Kouakou, YN; Nguyen, CA; Quintanar-Guerrero, D, 2006
)
0.33
"The purpose of this study was to develop a taste-masked quinine sulphate dosage form as a flexible pediatric formulation tool."( Quinine sulphate pellets for flexible pediatric drug dosing: formulation development and evaluation of taste-masking efficiency using the electronic tongue.
Cordella, C; Huyghebaert, N; Kayumba, PC; Ntawukuliryayo, JD; Remon, JP; Vervaet, C, 2007
)
0.34
"An electrostatic dry powder coating process for pharmaceutical solid dosage forms was developed for the first time by electrostatic dry powder coating in a pan coater system."( A novel electrostatic dry powder coating process for pharmaceutical dosage forms: immediate release coatings for tablets.
Chow, K; Ma, Y; Qiao, M; Zhang, L; Zhu, J, 2010
)
0.36
" The application of modifying subcoats is an easy and effective means to achieve sustained release from shellac-coated dosage forms."( Development of shellac-coated sustained release pellet formulations.
Farag, Y; Leopold, CS, 2011
)
0.37
" Pharmacokinetic profiling of orally dosed TL formulations in rats was also carried out using UPLC/ESI-MS."( Physicochemical and pharmacokinetic characterization of amorphous solid dispersion of tranilast with enhanced solubility in gastric fluid and improved oral bioavailability.
Aoki, Y; Kawabata, Y; Kojo, Y; Onoue, S; Yamada, S; Yamauchi, Y, 2012
)
0.38
" Both dosage forms disintegrated immediately (less than 40 s) in simulated saliva solutions."( Evaluation of Chlorpheniramine Maleate microparticles in orally disintegrating film and orally disintegrating tablet for pediatrics.
Almoazen, H; Brunson, E; Hu, Z; Johnson, J; Liu, M; Lou, H; Qu, W, 2014
)
0.4
" Formulation design, development and in-vitro evaluation used in this study may serve as rational approach for manufacturing taste-masked orodispersible dosage forms."( Design, development and in-vitro evaluation of diclofenac taste-masked orodispersible tablet formulations.
Breitkreutz, J; Gerber, F; Guhmann, M; Pöllinger, N; Preis, M; Weitschies, W, 2015
)
0.42
"Orally disintegrating tablet (ODT) is a user friendly and convenient dosage form."( Investigation on the effect of polymer and starch on the tablet properties of lyophilized orally disintegrating tablet.
Liew, KB; Peh, KK, 2021
)
0.62
"Orodispersible tablets (ODTs) and orodispersible films (ODFs) are solid oral dosage forms disintegrating or dissolving rapidly when placed in the mouth."( Orodispersible films and tablets with prednisolone microparticles.
Brniak, W; Jachowicz, R; Maślak, E, 2015
)
0.42
"The present study was aimed to prepare, taste-masked mini-tablets, which are easily swallowed dosage forms, primarily to be used by pediatric and geriatric patients."( Preparation and Evaluation of Hot-Melt Extruded Patient-Centric Ketoprofen Mini-Tablets.
Almutairy, BK; Alshehri, SM; Alshetaili, AS; Alsulays, BB; Feng, X; Morott, JT; Park, JB; Repka, MA; Tiwari, RV; Zhang, F, 2016
)
0.43
"Barrier coatings are frequently employed on solid oral dosage forms under the assumption that they prevent moisture sorption into tablet cores thereby averting premature degradation of moisture-sensitive active ingredients."( An investigation into moisture barrier film coating efficacy and its relevance to drug stability in solid dosage forms.
Basit, AW; Mwesigwa, E, 2016
)
0.43
"5:1) are promising CET carriers with efficient taste masking potential and might be further used in designing orodispersible dosage forms with CET."( Original research paper. Characterization and taste masking evaluation of microparticles with cetirizine dihydrochloride and methacrylate-based copolymer obtained by spray drying.
Amelian, A; Basa, A; Ciosek, P; Szekalska, M; Winnicka, K, 2017
)
0.46
" In view of oral solid dosage forms, various taste masking techniques can be applied encapsulating the active pharmaceutical ingredient (API) to prevent the interaction with the taste buds."( Multiparticulate system combining taste masking and immediate release properties for the aversive compound praziquantel.
Breitkreutz, J; Münster, M; Schmidt, C; Schoch, C, 2017
)
0.46
" For the first time, the co-ordinated use of fused deposition modelling (FDM), 3D printing and liquid dispensing to fabricate individualised dosage form on demand in a fully automated fashion has been demonstrated."( On demand manufacturing of patient-specific liquid capsules via co-ordinated 3D printing and liquid dispensing.
Alhnan, MA; Gollwitzer, V; Habashy, R; Okwuosa, TC; Soares, C; Timmins, P, 2018
)
0.48
" This dynamic dosing system maintained the advantages of FDCs while providing a superior flexibility of dosing range, hence offering an optimal clinical solution to hypertension therapy in a patient-centric healthcare service."( From 'fixed dose combinations' to 'a dynamic dose combiner': 3D printed bi-layer antihypertensive tablets.
Abbadi, I; Alhnan, MA; Aziz, D; Isreb, A; Isreb, M; Sadia, M; Selo, A; Timmins, P, 2018
)
0.48
" Through this work, we have demonstrated that by the implementation of predictive thermodynamic modelling, HDASD formulation design can be integrated into the HME process design to ensure the desired quality of the final dosage form."( The design and development of high drug loading amorphous solid dispersion for hot-melt extrusion platform.
Andrews, GP; Jacobs, E; Jones, DS; McCoy, CP; Tian, Y; Wu, H, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (113)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (1.77)18.2507
2000's19 (16.81)29.6817
2010's83 (73.45)24.3611
2020's9 (7.96)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 43.43

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index43.43 (24.57)
Research Supply Index4.75 (2.92)
Research Growth Index5.77 (4.65)
Search Engine Demand Index62.15 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (43.43)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (1.77%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (0.88%)4.05%
Observational0 (0.00%)0.25%
Other110 (97.35%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]